Health updates and
clinic news

Overview of the CA72-4 tumor marker

CA72-4 (Carbohydrate Antigen 72-4) is a high-molecular-weight glycoprotein found on the surface of various cancer cells, particularly gastric adenocarcinoma.

In clinical practice, CA72-4 serves as a tumor marker to support diagnosis, monitor treatment efficacy, and detect recurrence in gastric cancer. Unlike diagnostic imaging, this is a simple, minimally invasive blood test. It is frequently ordered alongside other markers like CEA and CA19-9 to enhance diagnostic value.

Clinical role of CA72-4

• Diagnostic support: Elevated levels are often found in gastric cancer patients, especially those with mucinous adenocarcinoma.

• Treatment assessment: Following tumor resection, CA72-4 levels typically drop significantly. Persistently high levels may suggest residual cancer cells.

• Recurrence monitoring: A secondary rise in CA72-4 is often an early indicator of recurrence or metastasis.

• Synergistic detection: Combining CA72-4 with CEA or CA19-9 significantly improves the accuracy of gastric cancer surveillance.

Normal vs. abnormal values

• Normal range: Typically < 6.9 U/mL (thresholds may vary by laboratory).

• Elevated levels: High concentrations suggest potential gastric cancer or other malignancies.

• Non-Gastric causes ofelevation:

  • Malignant: Ovarian, pancreatic, colorectal, or lung cancers.
  • Benign: Gastric ulcers or chronic liver disease may cause slight elevations.

⚠️ Important: CA72-4 should never be used as a standalone diagnostic tool. It must be interpreted alongside gastroscopy, histopathology (biopsy), and other clinical findings.

Sensitivity and specificity

• Sensitivity: Ranges from 28% to 80% for gastric cancer, peaking in mucinous adenocarcinoma cases.

• Specificity: High at 90% to 95%, meaning it rarely rises in healthy individuals.

• Comparison: CA72-4 offers higher specificity for gastric cancer than CEA or CA19-9, making it more useful for confirming malignancy, though it is less sensitive for early-stage detection.

Indications for testing

A CA72-4 test may be indicated for:

• Patients with suspicious symptoms (bloating, loss of appetite, unexplained weight loss, hematemesis, or melena).

• Confirmed gastric cancer patients for prognostic assessment and post-treatment monitoring (surgery, chemotherapy, or radiotherapy).

• Early detection of metastasis or recurrence.

• High-risk groups (family history, chronic gastric ulcers, or long-term H. pylori infection).

Limitations

• Non-absolute Specificity: Levels can rise due to non-gastric cancers or certain benign conditions.

• False Negatives: Many early-stage gastric cancer patients still show CA72-4 levels within the normal range.

• Monitoring Trends: A single result is less informative than observing fluctuations over time.

• Not a Substitute: It cannot replace endoscopy and biopsy, the gold standards for gastric cancer diagnosis.

Procedure and preparation

• Preparation: No fasting is required. Patients should inform their doctor of any current medications.

• Execution: A standard venous blood draw.

• Results: Typically available within 1–2 business days.

When do you need to see the doctor?

Seek medical advice immediately if you experience:

• Early satiety or persistent bloating.

• Rapid, unexplained weight loss.

• Dull pain in the epigastric region.

• Vomiting blood or passing black, tarry stools (melena).

• A history of ulcers, H. pylori, or family history of gastric cancer.

FAQ (Frequently Asked Questions)

1. Can CA72-4 detect gastric cancer in its early stages?

No. Its sensitivity is limited in early stages. Gastroscopy and biopsy remain the primary methods for early detection.

2. Does a high CA72-4 level mean I definitely have cancer?

No. It can be elevated due to other conditions. A definitive diagnosis requires an endoscopy and clinical correlation.

3. Is CA72-4 useful after I have already completed treatment?

Yes. It is vital for monitoring your recovery and detecting early signs of recurrence or metastasis.

4. Can I use CA72-4 screening instead of an endoscopy?

No. CA72-4 is not a general screening tool. Gastroscopy remains the most accurate method for early diagnosis.

5. How often should I repeat this test?

This depends on your specific case. Post-treatment patients are typically tested every 3–6 months.

Conclusion

The CA72-4 test is a vital tumor marker that provides significant value in the diagnosis, monitoring, and detection of gastric cancer recurrence, particularly when used in conjunction with other markers such as CEA and CA19-9. However, it is not a definitive diagnostic tool and cannot replace the gold-standard methods of endoscopy and biopsy.

A clear understanding of CA72-4's role helps patients feel more reassured during testing and fosters better collaboration with physicians for effective monitoring and long-term treatment.

To schedule a CA72-4 test and gastric health screening at DYM Medical Center Vietnam, please contact us:

• DYM Medical Center Saigon: Room B101-B103, Basement 1, mPlaza Saigon Building, No. 39 Le Duan, Sai Gon Ward, Ho Chi Minh City

• DYM Medical Center Phu My Hung: Room 3A01, 3A Floor, The Grace Building, 71 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City

• DYM Medical Center Hanoi: B1 Basement, Epic Tower, Alley 19 Duy Tan, Cau Giay Ward, Ha Noi

• Hotline: 1900 29 29 37